Tag Archives: JNP

Top 10 Medical Stocks To Buy Right Now

Small cap Internet of Medical Things (IoMT) company Biotricity, Inc (OTCBB: BTCY) has just announced that it will be expanding the scope of a previously approved clinical investigation of fetal heart rate variability (fHRV) to include maternal HRV and other key physiologic metrics for maximum predictive accuracy and efficiency. This is potentially a good area to be in due to the fact that high-risk pregnancies require extensive monitoring and care during the gestational period. High-risk pregnancies are also on the rise and now account for 6 – 8% of all pregnancies in the U.S. due in part to a rise in existing maternal health conditions (such as high blood pressure and obesity) and older parental age at the time of pregnancy. This means that the maternal and fetal monitoring market is growing rapidly and is expected to be worth $2.3 Billion by 2019. 

Top 10 Medical Stocks To Buy Right Now: Pimco Corporate & Income Stategy Fund(PCN)

Advisors’ Opinion:

  • [By Shane Hupp]

    PeepCoin (PCN) uses the hashing algorithm. Its launch date was September 26th, 2016. PeepCoin’s total supply is 56,576,323,977 coins and its circulating supply is 17,376,323,977 coins. PeepCoin’s official website is dapscoin.com. The official message board for PeepCoin is medium.com/dapscoinofficial. PeepCoin’s official Twitter account is @DAPScoin and its Facebook page is accessible here. The Reddit community for PeepCoin is /r/DAPSCoin.

  • [By Max Byerly]

    PeepCoin (CURRENCY:PCN) traded down 16.9% against the U.S. dollar during the 24 hour period ending at 23:00 PM Eastern on July 9th. During the last week, PeepCoin has traded 35.9% lower against the U.S. dollar. One PeepCoin coin can currently be bought for $0.0000 or 0.00000001 BTC on popular exchanges including Cryptohub, TradeOgre, Bleutrade and C-Patex. PeepCoin has a total market cap of $619,022.00 and approximately $25,154.00 worth of PeepCoin was traded on exchanges in the last 24 hours.

  • [By Ethan Ryder]

    News stories about PIMCO Corporate & Income (NYSE:PCN) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PIMCO Corporate & Income earned a news impact score of 0.05 on Accern’s scale. Accern also gave news articles about the investment management company an impact score of 46.3242910143552 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

  • [By Joseph Griffin]

    PeepCoin (CURRENCY:PCN) traded 70.2% higher against the dollar during the 24-hour period ending at 13:00 PM ET on August 14th. During the last week, PeepCoin has traded 1.4% higher against the dollar. One PeepCoin coin can currently be bought for $0.0000 or 0.00000000 BTC on popular cryptocurrency exchanges including Trade Satoshi, CoinExchange, C-Patex and Cryptopia. PeepCoin has a total market cap of $497,805.00 and $5,648.00 worth of PeepCoin was traded on exchanges in the last 24 hours.

Top 10 Medical Stocks To Buy Right Now: Aluminum Corporation of China Ltd(ACH)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Shares of Aluminum Corp. of China Limited (NYSE:ACH) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.70 and last traded at $10.71, with a volume of 2367 shares trading hands. The stock had previously closed at $11.00.

  • [By Max Byerly]

    Aluminum Corp. of China Limited (NYSE:ACH) has received an average rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company.

  • [By Jon C. Ogg]

    Aluminum Corp. of China Ltd. (NYSE: ACH) was trading up over 7% at $11.88 in New York trading. The 52-week range is $9.20 to $23.54.

    Century Aluminum Co. (NASDAQ: CENX) was down 13.3% at $10.30, and it now has a new 52-week range of $10.13 to $24.77, with that low being put in on the same day.

  • [By Logan Wallace]

    Banco de Sabadell S.A acquired a new position in Aluminum Corp. of China Limited (NYSE:ACH) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 25,227 shares of the basic materials company’s stock, valued at approximately $340,000.

  • [By Ethan Ryder]

    Aluminum Corp. of China Limited (NYSE:ACH) has been assigned a consensus recommendation of “Hold” from the eight research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company.

  • [By Max Byerly]

    Aluminum Corp. of China Limited (NYSE:ACH) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company.

Top 10 Medical Stocks To Buy Right Now: Minerva Neurosciences, Inc(NERV)

Advisors’ Opinion:

  • [By Max Byerly]

    Minerva Neurosciences (NASDAQ:NERV) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

    Nuvectra (NASDAQ:NVTR) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

  • [By Shane Hupp]

    AnaptysBio (NASDAQ: NERV) and Minerva Neurosciences (NASDAQ:NERV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

  • [By Lisa Levin] Gainers
    Carver Bancorp, Inc. (NASDAQ: CARV) shares jumped 92.1 percent to $7.01.
    iPic Entertainment Inc. (NASDAQ: IPIC) gained 21.6 percent to $9.73.
    Baozun Inc. (NASDAQ: BZUN) shares jumped 18.7 percent to $53.49 after reporting Q1 results.
    World Wrestling Entertainment, Inc. (NYSE: WWE) shares jumped 15.9 percent to $50.50. The company's "Smackdown Live" may not be renewed at NBCUniversal network and the company's "Monday Night Raw" program could be worth three times its current value elsewhere, according to a report for The Hollywood Reporter.
    Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) gained 14.7 percent to $ 20.46 after the company issued further details on Phase 3 ADVANCE study of ROLONTIS.
    Motus GI Holdings, Inc. (NASDAQ: MOTS) climbed 13.4 percent to $5.5009.
    Endocyte, Inc. (NASDAQ: ECYT) rose 13.3 percent to $ 14.23 after the company announced presentation of Phase 2 data from prostate cancer trial of 177Lu-PSMA-617 at the 2018 ASCO Annual Meeting.
    Diana Containerships Inc. (NASDAQ: DCIX) gained 12.9 percent to $1.7499 after the company announced the sale of Post-Panamax Container Vessel for $21 million.
    Essendant Inc. (NASDAQ: ESND) gained 12.7 percent to $12.43. Essendant confirmed receipt of unsolicited proposal from Staples of $11.50 per share in cash.
    Blink Charging Co (NASDAQ: BLNK) rose 11.8 percent to $8.04 after surging 31.68 percent on Wednesday.
    OptimumBank Holdings, Inc. (NASDAQ: OPHC) gained 11.5 percent to $5.15.
    Flotek Industries, Inc. (NYSE: FTK) shares climbed 10.7 percent to $3.74.
    Farmer Bros. Co. (NASDAQ: FARM) rose 7.9 percent to $25.95 after climbing 7.90 percent on Wednesday.
    Minerva Neurosciences Inc (NASDAQ: NERV) rose 6.5 percent to $6.93 after Journal of Clinical Psychiatry published positive results of cognitive performance from Phase 2B trial of roluperidone in schizophrenia patients.
    Williams Partners L.P. (NYSE: WPZ) rose 5.6 percent to $40

Top 10 Medical Stocks To Buy Right Now: Helen of Troy Limited(HELE)

Advisors’ Opinion:

  • [By Logan Wallace]

    Shares of Helen of Troy Limited (NASDAQ:HELE) have been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $115.75.

  • [By Motley Fool Staff]

    Helen of Troy Limited (NYSE: HELE)Q1 2019 Helen Of Troy Limited Earnings Conference callJul. 09, 2018, 1:00 pm ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Steve Symington]

    Shares of Helen of Troy Limited (NASDAQ:HELE) climbed 12.7% on Monday after the consumer brand housewares, health, home, and beauty products company announced strong fiscal first-quarter 2019 results.

  • [By Shane Hupp]

    Helen of Troy (NASDAQ:HELE) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a report released on Saturday.

  • [By Logan Wallace]

    Helen of Troy (NASDAQ:HELE) issued its quarterly earnings data on Tuesday. The company reported $1.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.59 by $0.39, Bloomberg Earnings reports. The firm had revenue of $393.50 million during the quarter, compared to analyst estimates of $349.19 million. Helen of Troy had a return on equity of 19.01% and a net margin of 4.84%. The business’s quarterly revenue was up 14.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.65 earnings per share. Helen of Troy updated its FY 2019 guidance to $7.65-7.90 EPS and its FY19 guidance to $7.65-7.90 EPS.

Top 10 Medical Stocks To Buy Right Now: Ionis Pharmaceuticals, Inc.(IONS)

Advisors’ Opinion:

  • [By Cory Renauer]

    Although Spinraza’s trajectory could quickly reverse, Biogen made a smart move by expanding its investment into the company that discovered it, Ionis Pharmaceuticals (NASDAQ:IONS). Unfortunately, Ionis probably won’t be adding any candidates to Biogen’s ultra-risky late-stage pipeline right away.

  • [By Chris Lange]

    Akcea Therapeutics Inc. (NASDAQ: AKCA) shares saw a nice bump on Wednesday after the company announced in conjunction with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) that they had received a marketing authorization approval from the European Commission (EC).

  • [By Cory Renauer]

    This Ionis Pharmaceuticals (NASDAQ:IONS) spinoff earned approval to market a rare disease drug called Tegsedi in the European Union earlier this year, but the U.S. Food and Drug Administration (FDA) won’t make a decision about the drug we also know as inotersen until October. In the meantime, the agency is expected to deliver an approval decision on or before August 30 for Waylivra, formerly volanesorsen, and the outcome is far from certain.

  • [By Dan Caplinger]

    Tuesday turned out to be a relatively quiet session on Wall Street, as the S&P 500 and other major benchmarks made modest gains to continue their impressive summer rally. Between favorable economic data and continued confidence in the lasting power of a bull market that’s approaching its 10th anniversary, investors seem inclined to accentuate the positive and ignore worries about future setbacks. Yet a few stocks did lose ground due to bad news affecting individual companies. Canopy Growth (NYSE:CGC), Mitek Systems (NASDAQ:MITK), and Ionis Pharmaceuticals (NASDAQ:IONS) were among the performers in the market. Here’s why they did so poorly.

Top 10 Medical Stocks To Buy Right Now: Juniper Pharmaceuticals, Inc.(JNP)

Advisors’ Opinion:

  • [By Chris Lange]

    Juniper Pharmaceuticals Inc. (NASDAQ: JNP) shares rallied early on Tuesday after the company announced that it would be acquired by Catalent. The transaction is expected to close in the third quarter of 2018.

Top 10 Medical Stocks To Buy Right Now: Points International, Ltd.(PCOM)

Advisors’ Opinion:

  • [By Max Byerly]

    News coverage about Points International (NASDAQ:PCOM) (TSE:PTS) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Points International earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news articles about the information services provider an impact score of 48.0880042366604 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

  • [By Joseph Griffin]

    Royal Bank of Canada reiterated their buy rating on shares of Points International (NASDAQ:PCOM) (TSE:PTS) in a report issued on Thursday morning. The brokerage currently has a $19.00 target price on the information services provider’s stock, up from their prior target price of $17.00.

  • [By Max Byerly]

    Points International Ltd. (NASDAQ:PCOM) (TSE:PTS) hit a new 52-week high and low on Wednesday . The stock traded as low as $15.08 and last traded at $15.00, with a volume of 402 shares traded. The stock had previously closed at $14.91.

  • [By Logan Wallace]

    Points International Ltd. (TSE:PTS) (NASDAQ:PCOM) insider Inez Mary Christine Murdoch sold 2,726 shares of the stock in a transaction dated Friday, June 29th. The stock was sold at an average price of C$21.12, for a total transaction of C$57,573.12.

Top 10 Medical Stocks To Buy Right Now: Targa Resources, Inc.(TRGP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    There’s just one problem with all that production: It needs to get out of the basin, which is a problem right now since there aren’t enough pipelines. Because of that, some of the best ways to play the Permian production boom are pipeline companies. Three perfectly positioned to profit from the Permian boom are Plains All American Pipeline (NYSE:PAA), Targa Resources (NYSE:TRGP), and Kinder Morgan (NYSE:KMI).

  • [By Matthew DiLallo]

    Meanwhile, Targa Resources (NYSE:TRGP) has been targeting investment opportunities focused on natural gas and NGLs and currently has more than $2 billion in projects under way. The company is one of the partners on Kinder Morgan’s Gulf Coast Express pipeline as well as on the proposed Whistler project that would also move gas out of the Basin. In addition to that, Targa is building the Grand Prix Pipeline, which will transport NGLs out of both the Permian and STACK shale play. These projects have the potential to nearly double Targa’s earnings by 2021.

  • [By Lee Jackson]

    This top energy MLP has had a string of positives lately. Targa Resources Corp (NYSE: TRGP) is a leading provider of midstream services and is one of the largest independent midstream energy companies in North America. Targa owns, operates, acquires and develops a diversified portfolio of complementary midstream energy assets.

  • [By Joseph Griffin]

    Shares of Targa Resources Corp (NYSE:TRGP) have been assigned a consensus rating of “Hold” from the twenty-four research firms that are covering the firm, MarketBeat Ratings reports. Thirteen investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $55.63.

  • [By Matthew DiLallo]

    Targa Resources (NYSE:TRGP) currently offers a well-above-average dividend that yields 6.6%. In exchange for that high yield, investors need to accept a higher level of risk since the company barely generates enough cash flow to cover that payout, which is one of several red flags.

Top 10 Medical Stocks To Buy Right Now: ConocoPhillips(COP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    According to a recent report by Reuters, ConocoPhillips (NYSE:COP) has held talks with investment banks about helping the company unload its stake in Cenovus Energy (NYSE:CVE). That sale could net the oil giant more than $2 billion in cash, which would bolster its already sizable cash war chest and give it more money to allocate in creating value for investors.

  • [By Chris Lange]

    The number of ConocoPhillips (NYSE: COP) shares short rose slightly to 21.33 million from the previous level of 21.01 million. Shares were trading at $64.79, within a 52-week range of $42.27 to $71.71.

  • [By Joseph Griffin]

    10 15 Associates Inc. lowered its holdings in ConocoPhillips (NYSE:COP) by 1.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 207,906 shares of the energy producer’s stock after selling 2,741 shares during the period. ConocoPhillips makes up 2.9% of 10 15 Associates Inc.’s holdings, making the stock its 8th biggest holding. 10 15 Associates Inc.’s holdings in ConocoPhillips were worth $12,327,000 as of its most recent SEC filing.

Top 10 Medical Stocks To Buy Right Now: National Western Life Group, Inc.(NWLI)

Advisors’ Opinion:

  • [By Ethan Ryder]

    National Western Life Group (NASDAQ:NWLI) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

  • [By Logan Wallace]

    National Western Life (NASDAQ: NWLI) and Brighthouse Financial (NASDAQ:BHF) are both finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

  • [By Stephan Byrd]

    Millennium Management LLC trimmed its holdings in shares of National Western Life Group Inc (NASDAQ:NWLI) by 64.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,115 shares of the financial services provider’s stock after selling 1,993 shares during the period. Millennium Management LLC’s holdings in National Western Life Group were worth $340,000 as of its most recent filing with the SEC.

Top 10 Performing Stocks To Buy For 2019

The Q3 2017 earnings report for large cap consumer electronics retail stock Best Buy Co Inc (NYSE: BBY) is scheduled before the market opens on Thursday (November 17th) as a technical chart shows shares still in an apparent uptrend albeit also appearing to have leveled off or be range bound since mid-August:

A long term performance chart shows shares of Best Buy Co all over the place, Aaron’s, Inc (NYSE: AAN) coming in flat for investors and hhgregg, Inc (NYSE: HGG) severely underperforming:

Top 10 Performing Stocks To Buy For 2019: Daxor Corporation(DXR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Verastem, Inc. (NASDAQ: VSTM) fell 9.7 percent to $4.73 in pre-market trading after announcing a $35 million common stock offering.
    Evolus, Inc. (NASDAQ: EOLS) shares fell 8 percent to $13.48 in pre-market trading ahead of regulatory update at 8:30 a.m. ET.
    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) fell 6.5 percent to $2.01 in pre-market trading after climbing 10.50 percent on Tuesday.
    Purple Innovation, Inc. (NASDAQ: PRPL) shares fell 5.8 percent to $9.36 in pre-market trading after reporting Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) fell 5.7 percent to $5.15 in pre-market trading after declining 5.04 percent on Tuesday.
    RYB Education, Inc. (NYSE: RYB) shares fell 5 percent to $16.39 in pre-market trading following Q1 results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares fell 4.4 percent to $4.30 in pre-market trading after rising 40.62 percent on Tuesday.
    Arbor Realty Trust, Inc. (NYSE: ABR) fell 4.4 percent to $8.92 in pre-market trading after announcing a 5.5 million share common stock offering.
    Daxor Corporation (NYSE: DXR) fell 4.1 percent to $7.32 in pre-market trading.
    Ormat Technologies, Inc. (NYSE: ORA) shares fell 3.8 percent to $51.03 in pre-market trading after the company announced plans to restate its Q2, Q3, Q4 and FY 2017 financial statements.
    Canadian Solar Inc. (NASDAQ: CSIQ) fell 3.5 percent to $16.20 in pre-market trading after reporting Q1 results.
    CELYAD SA/ADR (NASDAQ: CYAD) shares fell 3.3 percent to $29.70 in pre-market trading after the company reported launch of 1.8 million share offering

  • [By Logan Wallace]

    Daxor Co. (NYSEAMERICAN:DXR) saw a significant growth in short interest in the month of March. As of March 29th, there was short interest totalling 234,045 shares, a growth of 1,257.4% from the March 15th total of 17,242 shares. Based on an average daily trading volume, of 1,214,477 shares, the days-to-cover ratio is presently 0.2 days. Currently, 33.3% of the company’s shares are short sold.

Top 10 Performing Stocks To Buy For 2019: Vanda Pharmaceuticals Inc.(VNDA)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Todd Campbell]

    After it was announced yesterday that the stock would be added to the S&P 600 index, shares in Vanda Pharmaceuticals (NASDAQ:VNDA) jumped on Wednesday and were up 10% at 2 p.m. EDT. 

  • [By Stephan Byrd]

    Media stories about Vanda Pharmaceuticals (NASDAQ:VNDA) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.3857713397213 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $22.40.

Top 10 Performing Stocks To Buy For 2019: Martin Midstream Partners L.P.(MMLP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    ONEOK (NYSE:OKE) has made several shrewd moves over the past few years, which have positioned it to grow its high-yielding dividend at a high rate. One of the latest is its recent deal to buy out Martin Midstream Partners’ (NASDAQ:MMLP) 20% interest in the West Texas LPG pipeline system. With full control of that pipeline, the company can more aggressively pursue expansion opportunities, which recently led it to secure a second project on the system that positions it for even more growth in the future.

  • [By Matthew DiLallo]

    Master limited partnerships (MLPs) Buckeye Partners (NYSE:BPL) and Martin Midstream Partners (NASDAQ:MMLP) currently yield a jaw-dropping 13.7% and 17.4%, respectively. Both payouts are well above the 8% average yield of MLPs held in the Alerian MLP Index, which is a clear sign that the market doesn’t believe in the long-term viability of these payouts. Their unsustainability is even more apparent when we look at the embarrassingly weak financial profiles currently backing these payouts, which is why investors should steer clear of these high-yield stocks.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Martin Midstream Partners (MMLP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Martin Midstream Partners (MMLP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Performing Stocks To Buy For 2019: Halyard Health, Inc.(HYH)

Advisors’ Opinion:

  • [By Shane Hupp]

    Halyard Health (NYSE:HYH) updated its FY18 earnings guidance on Wednesday. The company provided EPS guidance of $1.65-$1.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.26.

  • [By Logan Wallace]

    Principal Financial Group Inc. lifted its stake in Halyard Health (NYSE:HYH) by 2.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 232,419 shares of the medical instruments supplier’s stock after purchasing an additional 6,411 shares during the period. Principal Financial Group Inc. owned 0.49% of Halyard Health worth $10,710,000 as of its most recent SEC filing.

  • [By Logan Wallace]

    Renaissance Technologies LLC acquired a new position in Halyard Health (NYSE:HYH) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 9,805 shares of the medical instruments supplier’s stock, valued at approximately $453,000.

Top 10 Performing Stocks To Buy For 2019: Juniper Pharmaceuticals, Inc.(JNP)

Advisors’ Opinion:

  • [By Chris Lange]

    Juniper Pharmaceuticals Inc. (NASDAQ: JNP) shares rallied early on Tuesday after the company announced that it would be acquired by Catalent. The transaction is expected to close in the third quarter of 2018.

Top 10 Performing Stocks To Buy For 2019: Canadian National Railway Company(CNI)

Advisors’ Opinion:

  • [By Paul Ausick]

    GE got some good news this past week with an order for 200 locomotives from Canadian National Railway Co. (NYSE: CNI). The locomotives will be built at GE’s plant in Fort Worth, Texas, and deliveries to the rail operator will begin next year. The balance of the locomotives will be delivered in 2019 and 2020.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Canadian National Railway (CNI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Neha Chamaria]

    Investing for really long periods of time, however, becomes easier if you bet on industry stalwarts that have consistently rewarded shareholders and possess strong growth catalysts to keep them going for years to come. I can think of four such “forever” stocks right now: Canadian National Railway (NYSE:CNI), Waste Management (NYSE:WM), Mastercard (NYSE:MA), and Visa (NYSE:V).

  • [By Motley Fool Staff]

    In this segment, Brendan Mathews — a member of the Stock Advisor research team, and the portfolio lead for Odyssey 2 and Supernova — talks about the lessons one can learn from the tale of Canadian National (NYSE:CNI), a Stock Advisor recommendation since 2008. One might expect a railroad company to be a steady, predictable performer, but its stock chart looks more like a roller coaster over that period. (And, as a bonus, they also chat a bit about the story of salesforce.com (NYSE:CRM), so stick around to the end.)

Top 10 Performing Stocks To Buy For 2019: Build-A-Bear Workshop, Inc.(BBW)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Dollar Tree, Inc. (NASDAQ: DLTR) is expected to report quarterly earnings at $1.23 per share on revenue of $5.56 billion.
    Express, Inc. (NYSE: EXPR) is projected to report quarterly loss at $0.02 per share on revenue of $466.25 million.
    Dollar General Corporation (NYSE: DG) is estimated to report quarterly earnings at $1.4 per share on revenue of $6.20 billion.
    Tech Data Corporation (NASDAQ: TECD) is expected to report quarterly earnings at $1.46 per share on revenue of $8.13 billion.
    Burlington Stores, Inc. (NYSE: BURL) is estimated to report quarterly earnings at $1.09 per share on revenue of $1.49 billion.
    Ciena Corporation (NYSE: CIEN) is projected to report quarterly earnings at $0.3 per share on revenue of $726.56 million.
    American Eagle Outfitters, Inc. (NYSE: AEO) is expected to report quarterly earnings at $0.22 per share on revenue of $806.17 million.
    Titan Machinery Inc. (NASDAQ: TITN) is estimated to report quarterly loss at $0.08 per share on revenue of $276.27 bmillion.
    Donaldson Company, Inc. (NYSE: DCI) is projected to post quarterly earnings at $0.52 per share on revenue of $682.68 million.
    Ship Finance International Limited (NYSE: SFL) is expected to report quarterly earnings at $0.21 per share on revenue of $92.08 million.
    Perry Ellis International, Inc. (NASDAQ: PERY) is projected to report quarterly earnings at $0.67 per share on revenue of $232.30 million.
    Kirkland's, Inc. (NASDAQ: KIRK) is estimated to report quarterly loss at $0.09 per share on revenue of $140.83 million.
    Build-A-Bear Workshop, Inc. (NYSE: BBW) is expected to report quarterly earnings at $0.18 per share on revenue of $90.20 million.
    J.Jill, Inc. (NYSE: JILL) is projected to report quarterly earnings at $0.19 per share on revenue of $160.50 million.
    Christopher & Banks Corporation (NYSE: CBK) is expected to report quarterly loss at $0.08 per share on revenue of $89.35 million.
  • [By Lisa Levin]

      

    Clearside Biomedical, Inc. (NASDAQ: CLSD) shares declined 32.19 percent to close at $9.86 on Thursday. Clearside Biomedical disclosed that its Phase 2 trial of CLS-TA met primary and secondary endpoints met in 6-month trial.
    scPharmaceuticals Inc. (NASDAQ: SCPH) shares dipped 30.1 percent to close at $9.94 on Thursday after the FDA identified deficiencies in the company’s New Drug Application for FUROSCIX. However, the FDA letter did not specify deficiencies identified and notification does not reflect final decision on information under review.
    Euroseas Ltd. (NASDAQ: ESEA) fell 24.08 percent to close at $1.86. Euroseas announced completion of the spin-off of its drybulk fleet into EuroDry Ltd.
    Golar LNG Limited (NASDAQ: GLNG) fell 25.09 percent to close at $25.98 following Q1 results.
    Oragenics, Inc. (NASDAQ: OGEN) shares dropped 25 percent to close at $1.50 on Thursday.
    Guess', Inc. (NYSE: GES) dropped 19.44 percent to close at $19.60 following Q1 results.
    Cantel Medical Corp. (NYSE: CMD) dropped 15.94 percent to close at $109.09 on Thursday following FQ3 results.
    Fusion Connect, Inc. (NASDAQ: FSNN) shares fell 15.55 percent to close at $3.91.
    Build-A-Bear Workshop, Inc. (NYSE: BBW) dropped 14.44 percent to close at $8.00 after reporting Q1 results.
    Dollar Tree, Inc. (NASDAQ: DLTR) shares declined 14.28 percent to close at $82.59 after the company reported weaker-than-expected earnings for its first quarter and lowered its FY2018 earnings guidance.
    Titan Machinery Inc. (NASDAQ: TITN) dropped 13.94 percent to close at $18.09 after reporting Q1 results.
    Co-Diagnostics, Inc. (NASDAQ: CODX) declined 13.17 percent to close at $2.90 after declining 5.65 percent on Wednesday.
    Concordia International Corp. (NASDAQ: CXRX) fell 12.89 percent to close at $0.2440 after the company announced that it would be delisted from the Nasdaq.
    Sears Holdings Corporation (NASDAQ: SHLD) slipped 12.46 percent

  • [By Joseph Griffin]

    News coverage about Build-A-Bear Workshop (NYSE:BBW) has been trending somewhat negative on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Build-A-Bear Workshop earned a media sentiment score of -0.07 on Accern’s scale. Accern also assigned media stories about the specialty retailer an impact score of 43.9525750448852 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Top 10 Performing Stocks To Buy For 2019: ING Group, N.V.(ISP)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Intesa Sanpaolo (BIT:ISP) received a €2.90 ($3.37) price target from research analysts at Deutsche Bank in a research note issued to investors on Wednesday. The firm presently has a “buy” rating on the stock.

  • [By Max Byerly]

    Intesa Sanpaolo (BIT:ISP) received a €3.00 ($3.53) price target from stock analysts at HSBC in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the stock. HSBC’s target price points to a potential downside of 2.60% from the stock’s current price.

  • [By Stephan Byrd]

    Goldman Sachs Group set a €2.90 ($3.37) price target on Intesa Sanpaolo (BIT:ISP) in a report published on Wednesday. The firm currently has a neutral rating on the stock.

  • [By Logan Wallace]

    Jefferies Financial Group set a €2.05 ($2.38) target price on Intesa Sanpaolo (BIT:ISP) in a report published on Tuesday. The brokerage currently has a neutral rating on the stock.

Top 10 Performing Stocks To Buy For 2019: Rite Aid Corporation(RAD)

Advisors’ Opinion:

  • [By Max Byerly]

    Rite Aid Co. (NYSE:RAD) dropped 6% during trading on Wednesday . The company traded as low as $1.88 and last traded at $1.89. Approximately 11,889,301 shares traded hands during trading, a decline of 37% from the average daily volume of 18,730,842 shares. The stock had previously closed at $2.01.

  • [By Keith Speights]

    Shares of major pharmacy chains CVS Health Corp. (NYSE:CVS), Rite Aid Corporation (NYSE:RAD), and Walgreens Boots Alliance Inc. (NASDAQ:WBA) sank by 9% or more as of 11:07 a.m. EDT on Thursday. All three stocks were impacted by the same big news: Amazon’s (NASDAQ:AMZN) acquisition of PillPack.

  • [By Max Byerly]

    Glen Harbor Capital Management LLC purchased a new position in shares of Rite Aid Co. (NYSE:RAD) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 220,096 shares of the company’s stock, valued at approximately $370,000.

Top 10 Performing Stocks To Buy For 2019: Bank of Nova Scotia (BNS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Bank of Nova Scotia (NYSE:BNS) (TSE:BNS) has earned an average rating of “Hold” from the eleven ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $94.00.

  • [By Shane Hupp]

    Bank of Nova Scotia (TSE:BNS) (NYSE:BNS) has been given an average recommendation of “Buy” by the thirteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is C$88.62.

  • [By Motley Fool Staff]

    Bank of Nova Scotia (NYSE:BNS)Q2 2018 Earnings Conference CallMay 29, 2018, 8:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Adam Borgatti — Vice President, Investor Relations

  • [By Stephan Byrd]

    Bank of Nova Scotia (TSE:BNS) (NYSE:BNS) insider Andrew Branion sold 332 shares of the firm’s stock in a transaction on Wednesday, October 10th. The shares were sold at an average price of C$74.49, for a total value of C$24,730.68.

Top Growth Stocks To Buy For 2019

German exports fell the most in more than five years at the start of 2018, holding back growth in Europe’s largest economy.

A breakdown of first-quarter gross domestic product data showed foreign sales fell 1 percent, the most since 2012. Imports also declined, and net trade knocked 0.1 percentage point off GDP.

#lazy-img-328015497:before{padding-top:56.25%;}

“The drop in exports could be a first sign that the appreciation of the euro in 2017 has started to leave its mark on the economy,” said Carsten Brzeski, an economist at ING-Diba in Frankfurt. But “strong private consumption, the pick-up of investments and low inventories still bode well for the German growth outlook.”

The euro has gained 11 percent against the dollar since the start of 2017. It was up 0.2 percent at $1.1717 as of 9 a.m. Frankfurt time.

Top Growth Stocks To Buy For 2019: Allstate Corporation (ALL)

Advisors’ Opinion:

  • [By Shane Hupp]

    Principal Financial Group Inc. cut its position in Allstate (NYSE:ALL) by 7.4% in the 1st quarter, HoldingsChannel.com reports. The firm owned 2,075,644 shares of the insurance provider’s stock after selling 165,995 shares during the quarter. Principal Financial Group Inc.’s holdings in Allstate were worth $196,771,000 as of its most recent SEC filing.

  • [By Shane Hupp]

    Allion (CURRENCY:ALL) traded up 4.4% against the US dollar during the 24 hour period ending at 8:00 AM Eastern on May 29th. One Allion coin can currently be purchased for $0.0143 or 0.00000193 BTC on popular exchanges including YoBit, Cryptopia and CoinExchange. Allion has a total market cap of $88,618.00 and $1,993.00 worth of Allion was traded on exchanges in the last 24 hours. During the last week, Allion has traded down 4.3% against the US dollar.

  • [By Stephan Byrd]

    Guggenheim Capital LLC grew its position in shares of Allstate Corp (NYSE:ALL) by 4.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 530,877 shares of the insurance provider’s stock after purchasing an additional 22,475 shares during the period. Guggenheim Capital LLC’s holdings in Allstate were worth $50,327,000 as of its most recent SEC filing.

  • [By Lee Jackson]

    Insurance companies tend to do well as rates rise, and this sector giant may be an outstanding pick for investors. Allstate Corp. (NYSE: ALL) is the largest publicly traded personal lines insurance company, with about 12% of the personal lines market (one in eight households). Allstate is primarily a direct writer. Besides a full array of personal lines P/C products (preferred, standard and nonstandard auto insurance, and homeowners’ insurance), the company also offers life insurance and annuity products.

Top Growth Stocks To Buy For 2019: Braskem S.A.(BAK)

Advisors’ Opinion:

  • [By Max Byerly]

    Aemetis (NASDAQ: AMTX) and Braskem (NYSE:BAK) are both oils/energy companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

  • [By Dan Caplinger]

    The stock market eased lower on Friday, but major benchmarks managed to come back considerably from their worst levels of the day. At its lows, the Dow Jones Industrial Average was down more than 200 points following news that the U.S. would indeed move forward with tariffs against China. Yet even though China announced plans to retaliate in kind, market participants seemed willing to give trade policy the benefit of the doubt given the current strength of the U.S. economy. Some stocks saw nice gains in response to the news, as well as to company-specific events. Schnitzer Steel Industries (NASDAQ:SCHN), Braskem (NYSE:BAK), and Pivotal Software (NYSE:PVTL) were among the best performers on the day. Here’s why they did so well.

  • [By Lisa Levin]

    Wednesday morning, the materials shares rose 0.83 percent. Meanwhile, top gainers in the sector included Intrepid Potash, Inc. (NYSE: IPI), up 8 percent, and Braskem S.A. (NYSE: BAK) up 6 percent.

  • [By Maxx Chatsko]

    Shares of Braskem (NYSE:BAK) rose 22% today after Brazil’s largest chemical manufacturer confirmed what investors had long suspected: Talks are under way for Dutch chemicals leader LyondellBasell Industries NV (NYSE:LYB) to acquire majority control of Braskem and gain a manufacturing footprint in South America. Rumors of such talks were first reported in October 2017, but both companies denied them.

  • [By Max Byerly]

    Millennium Management LLC cut its holdings in shares of Braskem SA (NYSE:BAK) by 40.9% in the 1st quarter, Holdings Channel reports. The firm owned 538,986 shares of the energy company’s stock after selling 372,581 shares during the period. Millennium Management LLC’s holdings in Braskem were worth $15,625,000 at the end of the most recent reporting period.

Top Growth Stocks To Buy For 2019: Juniper Pharmaceuticals, Inc.(JNP)

Advisors’ Opinion:

  • [By Chris Lange]

    Juniper Pharmaceuticals Inc. (NASDAQ: JNP) shares rallied early on Tuesday after the company announced that it would be acquired by Catalent. The transaction is expected to close in the third quarter of 2018.

Hot Financial Stocks To Own For 2019

12 Best Small Cities for Successful Aging: 2017

10 Most Tax-Friendly States for Retirees: 2017

13 Best & Worst Broker-Dealers: Q3 Earnings, 2017

Waddell & Reed Financial said Wednesday that is making several changes to its leadership team due to the departure of Thomas Butch, who was formerly head of its broker-dealer, marketing and certain mutual fund operations.

Shawn M. Mihal will become president of Waddell & Reed Inc. (WRI), the firm’s registered broker-dealer. Mihal has served as COO of the BD; he joined the unit as its chief regulatory and compliance officer in March 2015.

Nikki F. Newton will serve as president of Ivy Distributors Inc., or IDI, which distributes and underwrites Ivy Funds. He has been with the company since January 1998 and recently has been head of global relationships for Ivy Funds.

CFO Brent K. Bloss will act at Waddell & Reed’s chief operating officer; he will stay in the CFO role though Dec. 31. The company says its board plans to tap Chief Accounting Officer Benjamin R. Clouse as its CFO in 2018.

Hot Financial Stocks To Own For 2019: Camping World Holdings, Inc. (CWH)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Camping World (NYSE:CWH) was downgraded by research analysts at TheStreet from a “c-” rating to a “d+” rating in a note issued to investors on Tuesday.

  • [By ]

    Camping World (CWH) dropped as much as 17% in trading Tuesday after the company reported revenue growth of 21%, a deceleration from the previous quarter’s growth of 35%. Additionally, CEO Marcus Lemonis said that unseasonably cold weather likely impacted the early part of the industry’s peak selling season. 

  • [By Ethan Ryder]

    Camping World (NYSE:CWH) insider Marcus Lemonis acquired 8,000 shares of Camping World stock in a transaction that occurred on Wednesday, May 16th. The stock was acquired at an average price of $22.11 per share, with a total value of $176,880.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

  • [By Dan Caplinger]

    The stock market was mixed on Thursday, with strength for the Dow Jones Industrial Average standing in contrast to weakness among the key technology stocks in the Nasdaq Composite. For the most part, those impacts canceled each other out for the broader market, with theS&P 500 showing only minimal changes from yesterday’s levels. The volatility shows that investors generally have some uncertainty about the future direction of the market, but some stocks managed to post substantial gains. Camping World Holdings (NYSE:CWH), Axovant Sciences (NASDAQ:AXON), and Sonic (NASDAQ:SONC) were among the best performers on the day. Here’s why they did so well.

  • [By Steve Symington]

    Shares of Camping World Holdings Inc. (NYSE:CWH) were down 17.3% as of 3:00 p.m. EDT Tuesday after the RV dealer announced mixed first-quarter 2018 resultsand warned of a slow start to its peak selling season.

  • [By Rick Munarriz]

    One of last week’s biggest winners wasCamping World Holdings(NYSE:CWH), soaring 30.6% after getting a chance to defend its recent actions before national and Wall Street audiences. CEO Marcus Lemonis appeared on CNBC’s Mad Money, detailing the RV and outdoors enthusiast retailer’s growth prospects. It’s fitting, as Lemonis himself is the host of CNBC’s The Profit. He alsopresented at Baird’s Global Consumer, Technology & Services Conference.

Hot Financial Stocks To Own For 2019: The First of Long Island Corporation(FLIC)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on First of Long Island (FLIC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Financial Stocks To Own For 2019: Juniper Pharmaceuticals, Inc.(JNP)

Advisors’ Opinion:

  • [By Chris Lange]

    Juniper Pharmaceuticals Inc. (NASDAQ: JNP) shares rallied early on Tuesday after the company announced that it would be acquired by Catalent. The transaction is expected to close in the third quarter of 2018.

Best Low Price Stocks To Buy Right Now

Growth versus value investing is one of the major debates in the investment world.  Growth stocks seem to have outperformed their value counterparts over the past few years. But the winning streak of growth investing took a hit this year with value stocks regaining lost glory.

It is currently speculated that value investing will likely continue its winning run in the upcoming years. Hence, adding potential stocks to one’s portfolio might prove to be an ideal option in the current scenario.

Value vs. Growth Investing: Long-Drawn Debate

Value investors seek to invest in stocks that are believed to be trading at a discounted value. Investors look for favorable value ratios including low price-to-earnings (P/E) and price-to-book value (P/B) ratios to identify potential value stocks. While a significant number of these stocks are also expected to come with solid dividend payments, these stocks are also expected to moderate growth prospects.

Best Low Price Stocks To Buy Right Now: Coherent, Inc.(COHR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Rofin-Sinar Technologies (NASDAQ: RSTI) got a boost, shooting up 37 percent to $31.50 as Coherent, Inc. (NASDAQ: COHR) announced its plans to buy Rofin-Sinar Technologies Inc in a deal valued at around $942 million.

Best Low Price Stocks To Buy Right Now: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Matthew Briar]

    Biotricity Inc (OTCMKTS:BTCY) announced on Tuesday morning it was teaming up with Global to Local (G2L) to develop remote monitoring solutions that not only work, but serve the underserved (medically speaking) community. This partnership is of particular interest to current and would-be BTCY investors, as it will likely validate the crux of the work the company has done thus far.

    Biotricity is the developer of two different though related technologies. One is called bioflux, and the other is called biolife. Both are heart-monitoring devices… the former for use by caregivers in a clinical setting, while the latter is for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market next year. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device.

    The technology is unique, in that it not only provides stunningly accurate detailed information about a patient’s heart function, but it constantly feeds that data – remotely – to a caregiver and monitor that can make good use of that data. In August the company announced AT&T Inc. (NYSE:T) would be handling the wireless (cellular) connectivity between clinics and patients’ bioflux devices.

    It’s a breakthrough, for many reasons, not the least of which is that remote monitoring lowers overall healthcare costs for those patients, and ultimately, for insurers.

    The hardware is not yet available on a commercial basis, but it is being tested in a clinical setting. The Global to Local partnership will be another field test of sorts, validating the work Biotricity has performed on the R&D front.

    The organization says

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Robert J. Smith]

    Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.

  • [By James E. Brumley]

    Biotricity Inc (OTCMKTS:BTCY), a developer of remote health-monitoring devices, reminded us not so gently today that while it’s waiting on the last of the necessary approvals from the FDA for its hardware, it’s still moving the ball downfield (so to speak). That is to say, it’s already lined up a manufacturer for its so-called Bioflux cardiac monitor for when the last green light is given, and it’s a good one…. Providence Enterprise . That’s the same company that makes some of the equipment and goods within your sight right now.

    Biotricity is the name behind two pieces of technology, both of which are nearing the end of their development. One is the aforementioned Bioflux, and the other is called biolife…. the latter for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market this year. In fact, the company demonstrated its IoT-connected bioflux at this year’s Mobile World Congress (MWC) 2017 in Barcelona, Spain a couple of weeks ago. The crowd liked what it saw.

    The marketable version of the device isn’t available yet; it’s still going through the approval process. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device, and that portion of the review takes longer.

    Still, the company is rightfully optimistic, so much so that it’s already lined up a company to manufacture the Bioflux device once the final approval and final specs are in. That company is Providence Enterprise, which has a long history in making drug delivery and diagnostic equipment, as well as plenty of experience making electronics. The Bioflux will be a blend of both capabilities.

    It’s in

Best Low Price Stocks To Buy Right Now: Juniper Pharmaceuticals, Inc.(JNP)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Monday, our Under the Radar Moversnewsletter suggested shorting women’s health stock Juniper Pharmaceuticals (NASDAQ: JNP):

    Juniper Pharmaceuticals shares have yet to break under a key support level at $5.00. But, waiting until that happens may be too late. After some continued testing of that floor, if-and-when the support should break, the ensuing selloff could materialize in a hurry. If you’re not it at the time it happens, you may not be able to get in at a decent price.

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested shorting small cap women’s health therapeutic stock Juniper Pharmaceuticals (NASDAQ: JNP):